Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 18/20 | 0.87 |
| ▸ | MAPK3 | P27361 | 10/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13854522 | 0.93 | MAPK1 (1.00) | MAPK1MAPK3CYP3A4 | |
| SCHEMBL10235631 | 0.93 | MAPK1 (1.00) | MAPK1MAPK3CYP3A4 | |
| SCHEMBL13855030 | 0.89 | MAPK1 (0.91) | MAPK1MAPK3CYP3A4 | |
| SCHEMBL10235641 | 0.87 | MAPK1 (0.89) | MAPK1MAPK3CYP3A4 | |
| SCHEMBL10235573 | 0.85 | MAPK1 (1.00) | MAPK1MAPK3CYP3A4 | |
| SCHEMBL13854533 | 0.85 | MAPK1 (0.86) | MAPK1MAPK3 | |
| SCHEMBL10235595 | 0.84 | MAPK1 (1.00) | MAPK1MAPK3CYP3A4 | |
| SCHEMBL13854423 | 0.83 | MAPK1 (1.00) | MAPK1MAPK3 | |
| SCHEMBL13153466 | 0.83 | MAPK1 (1.00) | MAPK1MAPK3 | |
| SCHEMBL13854529 | 0.83 | MAPK1 (1.00) | MAPK1MAPK3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | MAPK1 1/4885MAPK3 6/4885CYP3A4 1326/4885 |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | MAPK1 277/4885MAPK3 489/4885CYP3A4 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.